Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04210310 · ClinicalTrials.gov registry record · Phase 3
High Dose Oxytocin Nasal Spray for Treatment of Tinnitus
A Phase 3 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 3
- Development phase
- 33
- Enrollment target
NCT04210310 is a Phase 3 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 33 participants.
The verdict
NCT04210310, a Phase 3 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of high-dose intranasal oxytocin for treating tinnitus. The hypothesis is that high dose intranasal oxytocin can significantly reduce tinnitus severity and disability.
Interventions
- DRUG Oxytocin
- OTHER Placebo nasal spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2022-05-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04210310
The ClinicalTrials.gov registry entry for NCT04210310 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxytocin is the first listed.
NCT04210310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04210310 about?
NCT04210310 is a clinical study titled "High Dose Oxytocin Nasal Spray for Treatment of Tinnitus". The purpose of this study is to evaluate the effects of high-dose intranasal oxytocin for treating tinnitus. The hypothesis is that high dose intranasal oxytocin can significantly reduce tinnitus severity and disability.
What is the current status of trial NCT04210310?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 33 participants. The study started on 2020-01-15. Estimated completion is 2022-05-10.
What interventions are being tested in trial NCT04210310?
The interventions under investigation include: Oxytocin (DRUG), Placebo nasal spray (OTHER).
Who is sponsoring clinical trial NCT04210310?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.